Duodenitis

Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors

Retrieved on: 
Tuesday, December 6, 2022

GUILFORD, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a biotechnology company developing an artificial intelligence-powered pipeline of precision therapeutics for highly debilitating gastrointestinal (GI) and hepatobiliary disorders, today announced the appointment of Mr. Jason Fenton to its Board of Directors. Mr. Fenton is a widely recognized healthcare-focused capital markets executive who brings over 20 years of experience.

Key Points: 
  • - Company also primed to advance additional programs, including a pan-inflammasome inhibitor
    GUILFORD, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a biotechnology company developing an artificial intelligence-powered pipeline of precision therapeutics for highly debilitating gastrointestinal (GI) and hepatobiliary disorders, today announced the appointment of Mr. Jason Fenton to its Board of Directors.
  • “We are honored to have a recognized advisor join our board of directors.
  • Jason has an outstanding depth and breadth of knowledge in the biotech and life sciences sectors and an unparalleled perspective on company building and capital formation,” said Krishnan Nandabalan, Ph.D., Chairman, President, and CEO, Invea Therapeutics.
  • Invea Therapeutics, Inc., or Invea, is a clinical-stage biotechnology company developing an artificial intelligence (AI) powered pipeline of precision therapeutics for highly debilitating gastrointestinal (GI) and hepatobiliary disorders.

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

Retrieved on: 
Monday, May 24, 2021

The results suggest that eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) may be an underrecognized cause of chronic unexplained GI symptoms in these patients, and that EG/EoD is highly underdiagnosed.

Key Points: 
  • The results suggest that eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) may be an underrecognized cause of chronic unexplained GI symptoms in these patients, and that EG/EoD is highly underdiagnosed.
  • These data suggest that EG/EoD may be associated with these unexplained chronic GI symptoms in these patients and that targeted EG/EoD therapies could provide a benefit.
  • In practice, gastroenterologists may not always take enough biopsies during upper endoscopy (EGD), especially in the absence of obvious mucosal abnormalities.
  • Published literature reports the prevalence of eosinophilic gastritis and/or eosinophilic duodenitis inthe United Statesto be approximately 50,000 people.

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

Retrieved on: 
Monday, November 2, 2020

In addition, the poster abstract (S1330) appears in the supplement to the October 2020 issue of the American Journal of Gastroenterology.

Key Points: 
  • In addition, the poster abstract (S1330) appears in the supplement to the October 2020 issue of the American Journal of Gastroenterology.
  • Eosinophilic gastritis, eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis), and eosinophilic esophagitis are chronic, often severe, inflammatory diseases characterized by the presence of high levels of eosinophils in the stomach, duodenum, or esophagus, respectively.
  • The current estimated prevalence of eosinophilic gastritis and eosinophilic duodenitis inthe United Statesis approximately 50,000 people.
  • The Company believes that these diseases may be significantly under-diagnosed, or misdiagnosed, as other gastrointestinal diseases.

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

Retrieved on: 
Wednesday, October 21, 2020

The peer-reviewed article, Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis, will also appear in the journals print issue.

Key Points: 
  • The peer-reviewed article, Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis, will also appear in the journals print issue.
  • Eosinophilic gastritis, eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis), and eosinophilic esophagitis are severe inflammatory orphan diseases characterized by the presence of high levels of eosinophils in the stomach, duodenum, or esophagus, respectively.
  • The current estimated prevalence of eosinophilic gastritis and eosinophilic duodenitis inthe United Statesis approximately 50,000 people.
  • The Companys lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE).